GlassScriptPhysician profile
Joseph M Compton
NPI 1023025202
$3,139.80
in general payments reported to CMS, 2019-2025
14 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $425 · 2023: $388 · 2024: $422 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.78 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,089.80 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $880.02 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $383.16 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $213.14 | 2024-2025 | Dupixent |
| Insmed, INC. | $149.07 | 2025 | Brinsupri, Arikayce |
| Grifols USA, LLC | $88.21 | 2023-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $64.39 | 2023 | Yupelri |
| Philips North America LLC | $62.05 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Novartis Pharmaceuticals Corporation | $57.26 | 2024 | |
| Verona Pharma, INC. | $47.89 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $34.72 | 2025 | Yupelri |
| Pfizer INC. | $33.64 | 2023-2025 | |
| Lilly USA, LLC | $19.46 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2024 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.